Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Ens-Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique (CNRS), Hospice Civils De Lyon
InventorsAntoine Sicard, Olivier Thaunat
Life of this patent
Estimating the term…
Abstract
The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.
Claims19
A nanoparticle,
- comprising a streptavidin coating and an amount of at least one antigen and an amount of at least one antibody having specificity for a human or mouse B cell receptor (BCR),
- wherein each of the at least one antigen and at least one antibody are attached to the surface of the nanoparticle via a linker having a biotin moiety and forming a streptavidin-biotin complex with the streptavidin coating, and
- wherein one of the at least one antigen is ovalbumin or a trimer HIV-GAG peptide, wherein the trimer HIV-GAG peptide has an amino acid sequence identity as set forth in SEQ ID NO:1.
A nanoparticle able to be internalized by B cells, comprising
- an organic polymer sphere having a size range of 100 to 500 nanometers;
- a streptavidin coating;
- a plurality of biotin linkers, wherein each biotin linker forms a streptavidin-biotin complex with the streptavidin coating;
- at least one antigen capable of eliciting a T-cell response monobiotinylated to a first biotin linker;
- and
- at least one antibody monobiotinylated to a second biotin linker, wherein said at least one antibody comprises specificity for the framework region of a mouse or human kappa or lambda B cell receptor (BCR) light chain or for the framework region of a mouse or human BCR heavy chain and is selected from the group consisting of rat anti-mouse kappa light chain(anti-κ mAb clone 187.1), mouse anti-human k light chain (clone G20-361), lambda light-chain (clone JC5-10) and human lambda light chain (clone JDC-12).
A nanoparticle, comprising
- a polystyrene sphere having a size of 400 nanometers;
- a streptavidin coating;
- a plurality of sulfo-NHS-LC-LC-biotin linkers forming streptavidin-biotin complexes with said streptavidin coating;
- an antigen, monobiotinylated to a first sulfo-NHS-LC-LC-biotin linker, wherein the antigen is ovalbumin or a trimer HIV-GAG peptide, wherein the trimer HIV-GAG peptide has an amino acid sequence as set forth in SEQ ID NO:1;
- and
- an antibody, monobiotinylated to a second sulfo-NHS-LC-LC-biotin linker, wherein the antibody is specific for the framework region of a mouse or human kappa or lambda B cell receptor (BCR) light chain or for the framework region of a mouse or human BCR heavy chain and is selected from the group consisting of rat anti-mouse kappa light chain(anti-κ mAb clone 187.1), mouse anti-human k light chain (clone G20-361), lambda light-chain (clone JC5-10) and human lambda light chain (clone JDC-12);
- wherein said nanoparticle is able to be internalized by B cells and is suitable for generating antigen-specific T cells.
Dependencies are inferred from the claim text.